Instituto de Salud Musculoesquelética-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2024

  1. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

2021

  1. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey

    Joint Bone Spine, Vol. 88, Núm. 4

2020

  1. Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study

    Reumatologia Clinica, Vol. 16, Núm. 2P1, pp. 116-119

2018

  1. Correction to: The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern (Rheumatology International, (2018), 38, 9, (1735-1740), 10.1007/s00296-018-4097-y)

    Rheumatology International

2017

  1. Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study

    Rheumatology International, Vol. 37, Núm. 7, pp. 1195-1202

  2. Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: A multicentre, non-interventional study

    Clinical and Experimental Rheumatology, Vol. 35, Núm. 3, pp. 423-430

  3. The Challenge of Assessing Adherence to Subcutaneous Biological Drugs in Immune-Mediated Inflammatory Diseases. Letter to the Editor Regarding Michetti P, Weinman J, Mrowietz U, et al. Adv Ther (2017);34:91–108. doi:10.1007/s12325-016-0441-3

    Advances in Therapy